380222-42-4

Basic information

• Product Name: N-(1-(pyridin-2-yl)piperidin-4-yl)-1H-imidazole-1-carboxamide
• Synonyms: N-(1-(pyridin-2-yl)piperidin-4-yl)-1H-imidazole-1-carboxamide
• CAS NO: 380222-42-4
• Molecular Weight: 271.322
• Mol File: 380222-42-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(1-(pyridin-2-yl)piperidin-4-yl)-1H-imidazole-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-(pyridin-2-yl)piperidin-4-yl)-1H-imidazole-1-carboxamide(380222-42-4)
• EPA Substance Registry System: N-(1-(pyridin-2-yl)piperidin-4-yl)-1H-imidazole-1-carboxamide(380222-42-4)

Safety Data

• Hazardous Substances Data: 380222-42-4(Hazardous Substances Data)

Upstream product

• 144465-94-1 4-amino-1-(pyridin-2-yl)piperidine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 380222-94-6 9-{(3AR,4R,6S,6AS)-6-[(ethylamino)carbonyl]-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl}-6-[(2,2-diphenylethyl)amino]-N-{2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl}-9H-purine-2-carboxamide 
• 380221-63-6 6-[(2,2-Diphenylethyl)amino]-9-{(2R,3R,4S,5S)-5-[(ethylamino)carbonyl]-3,4-dihydroxytetrahydro-2-furanyl}-N-(2-[({[1-(2-pyridinyl)-4-piperidinyl]amino}carbonyl)amino]ethyl)-9H-purine-2-carboxamide 
• 955967-37-0 [(1S,2R,3S,4R)-4-(6-(2,2-diphenyl-ethylamino)-2-{2-[3-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-ureido]-ethylcarbamoyl}-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-carbamic acid tert-butyl ester 
• 955970-76-0 N-[(1S,2R,3S,4R)-4-(6-(2,2-diphenyl-ethylamino)-2-{2-[3-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-ureido]-ethylamino}-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide trifluoroacetate 

Relevant articles and documents

ORGANIC COMPOUNDS

A compound of formula (I) and their preparation and use as pharmaceuticals wherein R1, R2 and R3 are as defined herein.

ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY

Compounds of (I), or stereoisomers or pharmaceutically acceptable salts thereof, where W, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.